Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NuVasive’s Osteocel Purchase, Spinal Sales Boost Stock 29% In Q2 – Index

This article was originally published in The Gray Sheet

Executive Summary

Investor enthusiasm for spinal device maker NuVasive's May acquisition of the biologic bone matrix product Osteocel, combined with stronger-than-expected corporate sales growth, helped drive NuVasive stock ahead 29% in the second quarter
Advertisement

Related Content

NuVasive buys biologic bone matrix product
Cyberonics Refocuses Sales And Marketing Effort On Epilepsy Treatment
Advertisement
UsernamePublicRestriction

Register

MT026333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel